Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Cancer.Melanoma.Ovarian Cancer.Lung Cancer.
Interventions
BIOLOGICAL

NY-ESO-1 combined with MPLA

Each patient will receive six doses of the formulation, administered intra-muscular, with an interval of 4 weeks between doses, and the first immunization performed 6 weeks after the completion of standard treatment. NY-ESO-1 (250 mcg) amd MPLA (100 mcg).

BIOLOGICAL

NY-ESO-1 combined with MPLA vaccine

Immunization os cancer patients with NY-ESO-1 combined with MPLA vaccine

Trial Locations (1)

Unknown

Hospital das Clinicas da FMUSP, São Paulo

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Butantan Institute

OTHER_GOV

lead

Instituto de Investigação em Imunologia

OTHER